Table 5

Influence of duration of anabolic-androgenic steroid self administration on lipoprotein variables and on recovery after cessation of use

BaselineEnd of AAS period6 weeks after drug cessation
Data are mean (SD).
The effects of AAS use for 8 weeks (n  =  9) are compared with administration for 14 weeks (n  =  10). For within group changes (compared with baseline values): *p<0.05, **p<0.01. For interaction effects (change after 8 weeks of AAS use compared with change by 14 weeks): †p<0.05.
AAS, Anabolic-androgenic steroid; Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; Lp(a), lipoprotein (a).
Triglycerides (mmol/l)
    8 weeks1.22 (0.37)1.34 (0.38)1.11 (0.39)
    14 weeks1.20 (0.32)1.12 (0.36)1.00 (0.24)
Total cholesterol (mmol/l)
    8 weeks4.23 (0.59)4.87 (1.54)4.41 (0.73)
    14 weeks4.88 (0.81)5.26 (1.48)4.98 (1.31)
HDL-C (mmol/l)
    8 weeks1.01 (0.25)0.47 (0.20)**0.89 (0.32)
    14 weeks1.14 (0.35)0.63 (0.30)**0.90 (0.49)*
HDL2-C (mmol/l)
    8 weeks0.23 (0.21)0.05 (0.04)*0.14 (0.13)*
    14 weeks0.19 (0.15)0.05 (0.04)*0.14 (0.18)
HDL3-C (mmol/l)
    8 weeks0.78 (0.12)0.43 (0.18)**0.74 (0.24)
    14 weeks0.96 (0.29)0.57 (0.30)**0.77 (0.38)
Apo-A1 (g/l)
    8 weeks1.39 (0.22)0.82 (0.29)**1.21 (0.34)
    14 weeks1.44 (0.31)0.91 (0.42)**1.10 (0.47)**
Apo-B (g/l)
    8 weeks0.90 (0.10)1.22 (0.23)*0.99 (0.09)
    14 weeks1.00 (0.14)1.32 (0.34)**1.16 (0.36)
Lp(a) (U/l)
    8 weeks68 (51)21 (26)**58 (68)
    14 weeks299 (410)42 (84)**142 (303)**†